BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vaxine Pty Ltd readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Vaxine Pty Ltd's drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03038802-10011@assetmemo.bio
DTSTAMP:20261121T010140Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Hepadvax: Phase 1/2 readout est. (NCT03038802)
DESCRIPTION:Hepadvax\, phase 1/2\, Chronic Hepatitis B.\nStudy: A Randomise
 d Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chron
 ic Hepatitis B Virus Infection\nEstimated primary completion: 1 March 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/hepadvax#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03038802
URL:https://assetmemo.bio/drug/hepadvax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
